BTX 9341
Alternative Names: BTX-9341Latest Information Update: 22 Jul 2024
At a glance
- Originator BioTheryX
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 degraders; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer
Most Recent Events
- 03 Jul 2024 Phase-I clinical trials in HER2-negative breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06515470)
- 03 Jul 2024 Phase-I clinical trials in HER2-negative breast cancer (Monotherapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06515470)
- 31 May 2024 Pharmacodynamics data from a preclinical studies in Glioblastoma and Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)